DK0507625T3 - Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner - Google Patents

Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner

Info

Publication number
DK0507625T3
DK0507625T3 DK92302992.0T DK92302992T DK0507625T3 DK 0507625 T3 DK0507625 T3 DK 0507625T3 DK 92302992 T DK92302992 T DK 92302992T DK 0507625 T3 DK0507625 T3 DK 0507625T3
Authority
DK
Denmark
Prior art keywords
beta
alpha
preparation
ketolactones
unsaturated
Prior art date
Application number
DK92302992.0T
Other languages
Danish (da)
English (en)
Inventor
Ryuji Ueno
Tomio Oda
Original Assignee
R Tech Ueno Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Tech Ueno Ltd filed Critical R Tech Ueno Ltd
Application granted granted Critical
Publication of DK0507625T3 publication Critical patent/DK0507625T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C07D307/935Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Furan Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK92302992.0T 1991-04-04 1992-04-03 Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner DK0507625T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP7148391 1991-04-04

Publications (1)

Publication Number Publication Date
DK0507625T3 true DK0507625T3 (da) 1996-09-16

Family

ID=13461939

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92302992.0T DK0507625T3 (da) 1991-04-04 1992-04-03 Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner

Country Status (11)

Country Link
US (1) US5229529A (enExample)
EP (1) EP0507625B1 (enExample)
JP (1) JPH089608B2 (enExample)
KR (1) KR970003125B1 (enExample)
AT (1) ATE141921T1 (enExample)
CA (1) CA2064481C (enExample)
DE (1) DE69213067T2 (enExample)
DK (1) DK0507625T3 (enExample)
ES (1) ES2093776T3 (enExample)
GR (1) GR3020903T3 (enExample)
TW (1) TW197439B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0643051T3 (da) * 1992-09-30 2000-04-17 R Tech Ueno Ltd Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
CA2178541C (en) 1995-06-07 2009-11-24 Neal E. Fearnot Implantable medical device
JP4358940B2 (ja) * 1999-08-26 2009-11-04 丸善石油化学株式会社 シクロヘキサンラクトン構造を有する重合性化合物及び重合体
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
AU2002240755B2 (en) * 2001-03-13 2007-07-05 Angiotech International Ag Micellar drug delivery vehicles and uses thereof
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
DK1392254T3 (da) 2001-04-20 2007-07-02 Univ British Columbia Micelle-lægemiddelindgivelsessystem for hydrofobe lægemidler
US20030216758A1 (en) * 2001-12-28 2003-11-20 Angiotech Pharmaceuticals, Inc. Coated surgical patches
DE10220729A1 (de) * 2002-05-08 2003-11-20 Martin Foerster Verfahren zum Bestimmen einer von Tieren gesoffenen Menge an flüssigen Nahrungsmitteln
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
EP1594459B1 (en) 2002-12-30 2010-02-17 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
US7989490B2 (en) * 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) * 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
MX2007001589A (es) * 2004-08-09 2007-08-02 Alios Biopharma Inc Variantes de polipeptido resistentes a proteasa, hiperglicosiladas sinteticas, formulaciones orales y metodos para utilizar las mismas.
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) * 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
US20070073385A1 (en) * 2005-09-20 2007-03-29 Cook Incorporated Eluting, implantable medical device
CA2637797C (en) * 2006-02-07 2015-03-17 R-Tech Ueno, Ltd. Method for preparing prostaglandin derivative
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
WO2008005284A2 (en) 2006-06-30 2008-01-10 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
US20080241215A1 (en) * 2007-03-28 2008-10-02 Robert Falotico Local vascular delivery of probucol alone or in combination with sirolimus to treat restenosis, vulnerable plaque, aaa and stroke
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) * 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
CA2724550C (en) 2008-05-22 2017-01-03 Kereos, Inc. Combination antitumor therapy
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
US8513441B2 (en) * 2008-08-29 2013-08-20 Alphora Research Inc. Prostaglandin synthesis and intermediates for use therein
EP2337563B1 (en) 2008-09-08 2014-04-09 The Board of Trustees of The Leland Stanford Junior University Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9198968B2 (en) 2008-09-15 2015-12-01 The Spectranetics Corporation Local delivery of water-soluble or water-insoluble therapeutic agents to the surface of body lumens
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
US9382272B2 (en) 2009-01-22 2016-07-05 Apotex Pharmachem Inc. Methods of making lubiprostone and intermediates thereof
WO2012149106A1 (en) 2011-04-29 2012-11-01 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
ES2653487T3 (es) 2013-02-15 2018-02-07 The Regents Of The University Of California Receptor de antígeno quimérico y métodos de uso del mismo
US9670162B2 (en) 2013-03-14 2017-06-06 The Board Of Trustees Of The Leland Stanford Junio Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
KR102320019B1 (ko) 2013-11-27 2021-11-01 레드우드 바이오사이언스 인코포레이티드 히드라지닐-피롤로 화합물 및 콘쥬게이트 제조 방법
US9879036B2 (en) 2014-02-19 2018-01-30 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase-2 binding compounds and methods of use thereof
KR20180058759A (ko) 2015-09-25 2018-06-01 제트와이 테라퓨틱스 인코포레이티드 폴리사카라이드-비타민 접합체를 포함하는 미립자를 기재로 하는 약물 제제
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELL-PENETRATING, GUANIDINIUM-LICH OLIGOPHOSPHOTRIESTER FOR ACTIVE AND SPILL-RELIEF
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
KR102783452B1 (ko) 2016-06-01 2025-03-19 세르비에 아이피 유케이 리미티드 폴리알킬렌 옥시드-아스파라기나제의 제형, 및 그의 제조 및 사용 방법
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
WO2018136570A1 (en) 2017-01-18 2018-07-26 F1 Oncology, Inc. Chimeric antigen receptors against axl or ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
EP3630189A4 (en) 2017-05-24 2021-06-23 The Board of Regents of The University of Texas System LINKER FOR ANTIBODY MEDICINAL CONJUGATES
US20210338686A1 (en) 2018-01-31 2021-11-04 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CA3096202A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
BR112020020930A2 (pt) 2018-04-11 2021-03-02 Ohio State Innovation Foundation composição de liberação de fármaco, método para tratar um distúrbio oftalmológico e kit
JP2021530507A (ja) 2018-07-18 2021-11-11 マンザニータ ファーマシューティカルズ,インク. 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法
US11529402B2 (en) 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
JP2022520220A (ja) 2019-02-14 2022-03-29 イグナイト イミュノセラピー インク 組換えワクシニアウイルスおよびその使用方法
JP7716623B2 (ja) 2019-04-02 2025-08-01 ウィリアム ロバート アラスーン リビング トラスト デイテッド オーガスト 29, 2016 排出ポンプ-癌抗原マルチ特異性抗体ならびにそれに関する組成物、試薬、キットおよび方法
AU2020402303A1 (en) 2019-12-12 2022-06-09 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
MX2022009355A (es) 2020-01-29 2022-09-02 Kenjockety Biotechnology Inc Anticuerpo anti-mdr1 y uso del mismo.
US20230192902A1 (en) 2020-06-04 2023-06-22 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
US20230212305A1 (en) 2020-06-04 2023-07-06 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
MX2023000734A (es) 2020-07-14 2023-02-13 Pfizer Virus vaccinia recombinante.
WO2022051390A1 (en) 2020-09-02 2022-03-10 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
WO2022103603A1 (en) 2020-11-13 2022-05-19 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
JP2023551203A (ja) 2020-11-20 2023-12-07 アール.ピー.シェーラー テクノロジーズ、エルエルシー 抗体-薬物コンジュゲートのためのグリコシド二重切断リンカー
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032576A (enExample) * 1976-01-08 1977-06-28
DE2655004C3 (de) * 1976-12-02 1980-06-19 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von bicyclischen Laktonen
DE3574470D1 (en) * 1985-09-18 1990-01-04 Upjohn Co Stereoselective reduktion.
JPS62153259A (ja) * 1985-12-26 1987-07-08 Sagami Chem Res Center (2−クロロ−3−オキソ−1−アルケニル)−ビシクロ〔3.3.0〕オクテン誘導体及びその製法
DE3620442A1 (de) * 1986-06-18 1987-12-23 Merck Patent Gmbh Ketolactone
DE3888542T2 (de) * 1987-09-04 1994-07-21 Upjohn Co Verfahren zur herstellung von prostaglandinzwischenprodukten.

Also Published As

Publication number Publication date
KR920019771A (ko) 1992-11-20
EP0507625B1 (en) 1996-08-28
GR3020903T3 (en) 1996-11-30
DE69213067D1 (de) 1996-10-02
EP0507625A1 (en) 1992-10-07
KR970003125B1 (ko) 1997-03-14
ATE141921T1 (de) 1996-09-15
JPH089608B2 (ja) 1996-01-31
ES2093776T3 (es) 1997-01-01
CA2064481A1 (en) 1992-10-05
DE69213067T2 (de) 1997-01-16
US5229529A (en) 1993-07-20
JPH0592965A (ja) 1993-04-16
CA2064481C (en) 1996-12-24
TW197439B (enExample) 1993-01-01

Similar Documents

Publication Publication Date Title
DK0507625T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketolactoner
ATE194601T1 (de) Verfahren zur herstellung von pyrimidinverbindungen
MX17846A (es) Proceso para la preparacion de nuevos derivados de 9h purina.
US4916250B1 (enExample)
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
UA8015A1 (uk) Спосіб одержання заміщених семікарбазонів або їх солей
ES551337A0 (es) Metodo de preparar derivados de b-carbolin-3-oxadiazolilo
IL80391A (en) Process for the preparation of decabromodiphenyl ether with improved thermal stability
ES2086065T3 (es) Preparacion de tetrahidropiridinas sustituidas.
HUT38623A (en) Process for production of derivatives of n-substituated neuramin-acid
ATE38986T1 (de) Verfahren zur herstellung 1,6-disubstituierter 2- aminobenzimidazole.
ES2057289T3 (es) Procedimiento para la obtencion de octadienoles.
DK0643051T3 (da) Fremgangsmåde til fremstilling af alfa,beta-umættede ketoner
ES2077781T3 (es) Procedimiento para la fabricacion de difosfanos solubles al agua.
ES2120098T3 (es) Procedimiento y productos intermedios para la preparacion de 5-oxaespiro(2.4)heptan-6-ona.
BG43004A3 (en) Method for preparing condensed as- triazines
GB2097792B (en) 1,3-dihydro-2h-imidazol-2-ones
DK93884A (da) Fremgangsmaade til fremstilling af 1,5-dibeskyttede-1,5,10-triazadecaner, mellemprodukter derfor samt disses fremstilling
ATE9462T1 (de) Verfahren zur herstellung der 2-(2,4dichlorphenoxy)-phenylessigsaeure.
IT1254985B (it) Procedimento per la fabbricazione di un materiale refrattario ceramico contenente carbonio
ES2070517T3 (es) Productos intermedios en la preparacion del acido 4,5-difluoroantranilico.
FI913012A0 (fi) Framstaellning av en hydroxiaromatisk ketoacetal fraon en hydroxiaromatisk metylketon och framstaellning av 5-(4-'hydroxifenyl) hydantoin och d-p-hydroxifenylglycin fraon 4-hydroxiacetofenon.
JPS5488210A (en) 4-methyl-3-sulphenyl-3-penten-2-one and its preparation